Patient Support

SpringWorks CareConnections® provides personalized support services and resources for patients taking OGSIVEO.

Connections at Each Point of Care

SpringWorks CareConnections provides personalized support services and resources to help your patients start and stay on track with OGSIVEO

Visit Site
SpringWorks CareConnections® logo

Coverage & Access Support

For eligible patients experiencing coverage delays or interruptions, our temporary free medication programs may help.

Quick Start Program

SpringWorks CareConnections can help eligible commercially insured patients who experience a qualified delay in their insurance coverage get started on OGSIVEO at no cost for a limited period of time*

Bridge Program

Eligible commercially or government-insured patients currently on OGSIVEO who experience a qualified lapse in their insurance coverage may be able to receive OGSIVEO at no cost for a limited period of time.*

View Resources & Forms

Terms and conditions apply. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Financial assistance

We’ll connect your patients to options that may be available.

Commercial Copay Program

Eligible patients with commercial insurance may pay as little as a $0 copay for OGSIVEO†

To find out if your patient is eligible for the Commercial Copay Program, contact SpringWorks CareConnections at 844-CARES-55 (844-227-3755), 
Monday – Friday 8 AM – 10 PM ET, to speak with a Nurse Advocate.

Learn More

Patient Assistance Program

Patients who are uninsured, underinsured, or lack coverage for OGSIVEO may be eligible to receive medication at no cost.‡

Terms and conditions apply. Copay program is subject to an annual benefit maximum. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Terms and conditions apply. PAP eligibility criteria and annual household income limits apply. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755)


PAP, patient assistance program.

Personalized Educational and Emotional Support

SpringWorks CareConnections Nurse Advocates serve as a single point of contact for your patients throughout their treatment journey with OGSIVEO and can provide personalized educational and emotional support to patients enrolled in the program upon request§

For further information or questions about enrolling your patients, contact SpringWorks CareConnections today

The SpringWorks CareConnections Patient Support Program is not intended to take the place of the healthcare provider, and our team of Nurse Advocates cannot provide medical or clinical advice.

Field Access Manager (FAM) Capabilities

FAMs can provide in-person or virtual support to help facilitate access to OGSIVEO by providing you and your office staff regional payor education and timely responses to questions.

Connect with a FAM

Enrolling Your Patients in SpringWorks CareConnections Is Simple

Download and print or complete the editable PDF:

  1. Download the enrollment form
  2. Complete and sign the enrollment form
  3. Fax the form to SpringWorks CareConnections at 844-227-3747

Your patient is also required to complete the patient section of the form and sign the corresponding authorizations to enroll in the program. We will contact your patient to obtain this information.

ePrescribe directly to SpringWorks CareConnections Pharmacy:

Pharmacy Name: PharmaCord Pharmacy

NCPDP Number: 1836191

Pharmacy Address: 11001 Bluegrass Parkway, Suite 200, Louisville, KY 40299

Phone Enrollment:

Call SpringWorks CareConnections at: 844-227-3755 and provide the information needed for program enrollment

Independent Patient Assistance Foundations‖

Financial assistance may be available through independent foundations that are not controlled by or otherwise affiliated with SpringWorks Therapeutics. These foundations may be able to assist with copays, premiums, patient education, social services, etc.


SpringWorks Therapeutics does not influence or control the operations of independent patient assistance foundations and cannot guarantee assistance will be provided. Details and eligibility requirements can be found directly on the individual foundation websites.
Explore additional foundations that may be able to help with financial assistance.

This link is created by Real Endpoints. Real Endpoints is independent of SpringWorks Therapeutics. SpringWorks is providing a link to these foundations to help patients find more information about potential assistance, but inclusion on this list does not represent an endorsement or a recommendation from SpringWorks for any group or organization.

View Foundations

Resources & Support for Patients

Encourage patients to take advantage of resources available to them for support, education, reminders, and more.

See All Resources

How to Order

Learn how to prescribe OGSIVEO through a Specialty Pharmacy network or medically integrated dispensing (MID) pharmacy.

Learn More

Request a Rep

Learn more about OGSIVEO by speaking with a SpringWorks representative.

Submit Request

NEXT PAGE

Resources
close
Resources
Indication
Important Safety Information

Indication 

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Important Safety Information

Warnings And Precautions

Diarrhea: Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.

Ovarian Toxicity: Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.

Hepatotoxicity: ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations (>5 x ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.

Non-Melanoma Skin Cancers: New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.

Electrolyte Abnormalities: Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.

Embryo-Fetal Toxicity: OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

Adverse Reactions

The most common (≥15%) adverse reactions were diarrhea (84%), ovarian toxicity (75% in the 36 females of reproductive potential), rash (68%), nausea (54%), fatigue (54%), stomatitis (39%), headache (30%), abdominal pain (22%), cough (20%), alopecia (19%), upper respiratory tract infection (17%), and dyspnea (16%).

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in ≥2% of patients were ovarian toxicity (4%).

The most common laboratory abnormalities (≥15%) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

Drug Interactions

CYP3A Inhibitors and Inducers: Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.

Gastric Acid Reducing Agents: Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

Please click here for full Prescribing Information.

Indication 

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Please click here for full Prescribing Information.

HCP, healthcare professional; PAP, patient assistance program.

References
  1. test ref patient supp